Daniel Goldstein

Daniel Goldstein

Auto-generated profile, based on publicly available information

Daniel Goldstein

Department of Internal Medicine, The Ohio State University, Columbus, OH

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2021 in Blood
Verified
Journal Article
Closed access
PDF file
AKAdam S Kittai
Adam S Kittai
CMCecelia R Miller
Cecelia R Miller
DGDaniel Goldstein
Daniel Goldstein
YHYing Huang
Ying Huang
LALynne V. Abruzzo
Lynne V. Abruzzo
JWJennifer A. Woyach
Jennifer A. Woyach
Complex karyotype, defined as ≥3 cytogenetic abnormalities, is prognostic of survival in patients treated with ibrutinib or venetoclax in relapsed/refractory (RR) chronic lymphocytic leukemia (CLL). Recent studies re-evaluating this dichotomous variable have shown that higher numbers of cytogenetic abnormalities (ie, ≥5) have a worse overall survival in patients treated with chemoimmunotherapy. We sought to determine if increasing karyotypic complexity, treated as a continuous variable, was prognostic of survival for patients treated with ibrutinib for CLL. We conducted a retrospective analysis of all patients with CLL treated with single-agent ibrutinib or in combination with an anti–CD20 antibody at our institution. We included 456 patients with both treatment-naive and RR disease. Median number of prior therapies was 2 (range, 0-13), 30% of patients had presence of del(17p), and 75% expressed unmutated IGHV. Fifty percent had ≥3 cytogenetic abnormalities, including 30% with ≥5. In a multivariable analysis, increasing karyotypic complexity was an independent predictor of shorter progression-free survival (hazard ratio, 1.07; 95% confidence interval, 1.04-1.10; P < .0001) and overall survival (hazard ratio, 1.09; 95% confidence interval, 1.05-1.12; P < .0001). Furthermore, we found that presence of clonal evolution determined by cytogenetic analysis at progression was prognostic of subsequent survival (P = .02). This solidifies karyotypic complexity as an important prognostic factor for patients with CLL treated with ibrutinib. Further research should consider sequential karyotypic analysis as a determination of risk of progression and death in patients with CLL.

1 March 2021 in Current Problems in Cancer: Case Reports
Verified
Journal Article
Open access
DGDan Goldstein
Dan Goldstein
SISteven Ing
Steven Ing
JOJason Jimenez Ocasio
Jason Jimenez Ocasio
MCMathew A Cherian
Mathew A Cherian